# EDGAR Filing Document

**Accession Number:** 0001177648
**File Stem:** 0001062993-25-015414
**Filing Date:** 2025-9
**Character Count:** 10467
**Document Hash:** 9f77e8d3189d7f78bd04cb748a9c3f19
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001062993-25-015414.hdr.sgml**: 20250908

**ACCESSION NUMBER**: 0001062993-25-015414

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250826

**FILED AS OF DATE**: 20250908

**DATE AS OF CHANGE**: 20250908

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Trout Harry R. III
- **CENTRAL INDEX KEY:** 0002085123

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35839
- **FILM NUMBER:** 251301132

**MAIL ADDRESS:**
- **STREET 1:** C/O ENANTA PHARMACEUTICALS, INC.
- **STREET 2:** 4 KINGSBURY AVENUE
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ENANTA PHARMACEUTICALS INC
- **CENTRAL INDEX KEY:** 0001177648
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 043205099
- **FISCAL YEAR END:** 0930

**BUSINESS ADDRESS:**
- **STREET 1:** 4 KINGSBURY AVENUE
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472
- **BUSINESS PHONE:** 617 607 0800

**MAIL ADDRESS:**
- **STREET 1:** 4 KINGSBURY AVENUE
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472

## Ex-24

```

POWER OF ATTORNEY

Know all by these presents that the undersigned hereby constitutes and appoints
each of Jay R. Luly, Matthew Kowalsky, Stacie Aarestad
and Ryan Rourke Reed, or each of them acting individually, the undersigned's
true and lawful attorney-in-fact to:

(1) execute for and on behalf of the undersigned a Form ID application to
be filed with the Securities and Exchange Commission to obtain EDGAR codes for
the undersigned;

(2) execute for and on behalf of the undersigned Forms 3, 4, and 5 with respect
to the securities of Enanta Pharmaceuticals, Inc. (the "Company") in
accordance with Section 16(a) of the Securities Exchange Act of 1934 and the
rules thereunder;

(3) do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such Form ID
application or Form 3, 4, or 5, complete and execute any amendment or
amendments thereto, and timely file such forms with the United States
Securities and Exchange Commission and any stock exchange or similar
authority; and

(4) take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit
to, in the best interest of, or legally required by, the undersigned, it
being understood that the documents executed by such attorney-in-fact on
behalf of the undersigned pursuant to this Power of Attorney shall be in
such form and shall contain such terms and conditions as such
attorney-in-fact may approve in such attorney-in-fact's discretion.

       The undersigned hereby grants to each such attorney-in-fact full
power and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the
rights and powers herein granted, as fully to all intents and purposes as
the undersigned might or could do if personally present, with full power
of substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes,
shall lawfully do or cause to be done by virtue of this power of attorney
and the rights and powers herein granted. The undersigned acknowledges
that the foregoing attorneys-in-fact, in serving in such capacity at the
request of the undersigned, are not assuming, nor is the Company assuming,
any of the undersigned's responsibilities to comply with Section 16 of the
Securities Exchange Act of 1934, as amended.

       This Power of Attorney shall remain in full force and effect until
the undersigned is no longer required to file Forms 3, 4, and 5 with respect
to the undersigned's holdings of and transactions in securities issued by
the Company, unless earlier revoked by the undersigned in a signed writing
delivered to the foregoing attorneys-in-fact.

      IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney
to be executed as of this 27th day of August, 2025.

       By: /s/ Harry R. Trout III
       Print Name: Harry R. Trout III

       (Signature page to Section 16 Power of Attorney for Enanta)

```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Trout Harry R. III<br><sub>(Last) (First) (Middle)</sub><br>C/O ENANTA PHARMACEUTICALS, INC.<br>4 KINGSBURY AVENUE<br><sub>(Street)</sub><br>WATERTOWN, MA 02472<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>ENANTA PHARMACEUTICALS INC [ ENTA ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2025-08-26 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Vice President, Finance_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 10912<sup>(1)</sup> | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Option (right to buy) | <sup>(2)</sup> | 2028-11-16 | Common Stock | 7110 | $81.20 | D |  |
| Stock Option (right to buy) | <sup>(2)</sup> | 2029-11-18 | Common Stock | 10000 | $63.35 | D |  |
| Stock Option (right to buy) | <sup>(2)</sup> | 2030-11-20 | Common Stock | 4987 | $43.57 | D |  |
| Stock Option (right to buy) | <sup>(3)</sup> | 2031-11-19 | Common Stock | 6048 | $75.33 | D |  |
| Stock Option (right to buy) | <sup>(4)</sup> | 2032-11-23 | Common Stock | 5571 | $45.00 | D |  |
| Stock Option (right to buy) | <sup>(5)</sup> | 2033-11-22 | Common Stock | 9075 | $8.99 | D |  |
| Stock Option (right to buy) | <sup>(6)</sup> | 2034-11-27 | Common Stock | 10175 | $8.83 | D |  |

---

### Footnotes:

(1) Consists of 762 shares of common stock held by the reporting person and 10,150 shares of common stock underlying unvested restricted stock units ("RSUs") granted under the Enanta Pharmaceuticals, Inc. ("Enanta") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs will vest and settle as follows: (i) 359 RSUs will vest and settle on December 1, 2025, (ii) 1,300 RSUs will vest and settle in two substantially equal annual installments beginning on December 4, 2025, (iii) 3,403 RSUs will vest and settle in three substantially equal annual installments beginning on December 4, 2025, and (iv) 5,088 RSUs will vest and settle in four substantially equal annual installments beginning on December 1, 2025.

(2) 100% of the shares subject to the option are fully vested and exercisable.

(3) Such option has or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 19, 2021).

(4) Such option has or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 23, 2022).

(5) Such option has or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 22, 2023).

(6) Such option has or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 27, 2024).

**Remarks:**
Exhibit 24 Power of Attorney filed herewith.

**Signature:** /s/ Matthew Kowalsky as attorney-in-fact  
**Date:** 2025-09-08

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**